This New Ransomware Can Irrevocably Destroy Your Files — Backup Now
Anubis rasnomware can destroy your files. Forever.
As if the threat from high-profile ransomware actors wasn't critical enough, with the Federal Bureau of Investigation issuing warnings as attacks skyrocket, and ransoms follow suit with, on occasion, ridiculously eye-watering payments demanded, a new ransomware-as-a-service platform has just upped the stakes since again. This time, as well as stealing your data and encrypting your files, the Anubis attackers install a custom wiper that can permanently and irrevocably destroy them at the whim of the hackers.
There has been some notable success in disrupting ransomware attackers of late, with devastating strikes by the FBI and Secret Service as well as hackers attacking some of the leading organized ransomware criminal groups. The problem is that as one group is disrupted or disbands, another rises to take their place in the cybercriminal hierarchy. And these groups often bring new and worrying attack tactics with them. Such is the case with the Anubis ransomware-as-a-service platform.
'Anubis is an emerging ransomware-as-a-service group that adds a destructive edge to the typical double-extortion model with its file-wiping feature,' Trend Micro threat researchers Maristel Policarpio, Sarah Pearl Camiling and Sophia Nilette Robles, said in a new report that takes a deep technical dive into the workings of the latest ransomware threat.
In an attempt to both set itself apart from other ransomware-as-a-service operations and twist the victim extortion leverage knife even further, Anubis employs a file wiper that, the researchers said, is 'designed to sabotage recovery efforts even after encryption.' This wiper uses a /WIPEMODE parameter to permanently delete the file contents and prevent any attempts at recovery.
We know that the Anubis attackers employ a number of methods to deploy the ransomware and execute its feature set, including phishing, command line execution and privilege escalation, not to mention the file-wiping capabilities already discussed. Mitigation strategies, therefore, are relatively straightforward.
Let's start with the big one, to mitigate the file-wiper impact. Backup and backup now. Ensuring that you have current offline and even off-site backups is your best defense against the Anubis eraser ransomware.
The remainder are nothing new either, as Trend Micro points out:
Do all of this and, suddenly, the Anubis ransomware threat becomes a lot less scary. Which isn't the same as saying it can be dismissed, as that would be a very poor and dangerous business decision indeed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Boy, 11, shot in North Lawndale park, police say
An 11-year-old boy was shot and injured at a North Lawndale park Saturday afternoon, according to Chicago police. Police said an unknown gunman shot the boy in his lower back just before 5:30 p.m. at Franklin Park in the 1400 block of South Tripp Avenue, police said. He was transported to Stroger Hospital in good condition. Police said no suspects were in custody, and that detectives' investigation was underway.
Yahoo
28 minutes ago
- Yahoo
Workiva Inc. (WK) Appoints Astha Malik to Its Board of Directors
Workiva Inc. (NYSE:WK) is one of the 11 Best Tech Stocks to Buy On the Dip. On May 29, Workiva Inc. (NYSE:WK) announced the appointment of Astha Malik, Chief Business Officer of Braze, to its board of directors. Malik brings 25 years of experience in driving growth and scaling high-growth SaaS companies. The company also released its Q1 2025 results on May 1. The revenue of $206 million grew 17% year-over-year driven by a 20% increase in subscription and support revenue. Both of these financial indicators surpass management's guidance despite a challenging environment characterized by a cautious buying environment and flat professional services revenue. A software engineer debugging a compliance code on a laptop in a modern office setting. After the earnings release, analyst Alexander Sklar from Raymond James maintained an Overweight rating on Workiva Inc. (NYSE:WK) lowering the price target from $125 to $105. The analyst noted the company showed strong bookings in Q1 however, the tough macroeconomic environment led to a conservative outlook by Raymond James. Regardless, Workiva Inc. (NYSE:WK) maintained its full-year revenue guidance at $864 million to $868 million. Workiva Inc. (NYSE:WK) is a technology company that operates a cloud-based platform that enables organizations to streamline and automate financial, sustainability, and compliance reporting processes. Its SaaS platform combines ERP, HCM, and CRM applications, supporting real-time collaboration and integrated reporting across teams. While we acknowledge the potential of WK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Melden Sie sich an, um Ihr Portfolio aufzurufen.
Yahoo
28 minutes ago
- Yahoo
Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is one of the 10 biotech stocks screaming a buy. On June 17, Citi initiated coverage of the stock with a 'Buy' rating and a $72 price target. The research firm remains bullish about the company's prospects owing to the strong potential of its drug candidates. A scientist in a lab coat examining a Petri dish containing a biopharmaceutical culture. The company's partnership with Takeda on Rusfertide to treat polycythemia Vera (PV) and oral IL-23 (icotrokinra) is one of the developments that underscore the research firm's favorable rating. Rusfertide demonstrated strong potential in PV patients in phase 3 trials, affirming its potential to address unmet needs. Citi is especially bullish about adding Rusfertide to existing therapies to expand its use case. In addition, the firm echoed the company's strategic partnership with Johnson & Johnson for multiple inflammation indications. According to Citi, Protagonist Therapeutics shares have outperformed over the past three months, going up by a 40% gain compared to a 2% gain of the S&P 500. It expects the company's combined revenues to climb to $700 million by 2032, above consensus estimates of $680 million. Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is a biopharmaceutical company that develops peptide-based drugs to treat various diseases, including rare and prevalent ones. Its pipeline includes treatments for blood disorders like polycythemia Vera and inflammatory conditions like ulcerative colitis and psoriasis. While we acknowledge the potential of PTGX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
